The Latest
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
Servier’s buyout of Day One is the year’s second-largest biotech acquisition so far, trailing only Gilead’s $7.8 billion purchase of cell therapy maker Arcellx.
Updated 7 hours ago -
Courtesy of Teva Pharmaceutical
Blackstone puts $400M into Teva, Sanofi gut disease drug
The deal adds to a growing biotech presence for Blackstone and supports testing of a drug competing with rival therapies from Merck and Roche.
-
Getty Images
News roundupPfizer nabs first obesity approval; Alnylam, Tenaya search for heart drugs
The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.
-
Getty Images
Emerging biotechA startup making drugs for blood disorders banks $160M
Atavistik Bio is using the cash to develop “allosteric” medicines it believes can precisely impact on diseases like myelofibrosis and the blood condition HHT.
-
Alamy
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA
The agency acted after reviewing mouse data submitted in 2024, making the timing of the new pause “confusing,” one analyst wrote.
-
Maddie Meyer via Getty Images
VaccinesModerna to pay up to $2.25B to end mRNA vaccine patent fight
Announced days before a trial, the deal settles a longstanding dispute and avoids what one analyst called a “worst-case scenario” financially for Moderna.
-
Getty Images
Gene editingPrime to test FDA flexibility with 2-patient gene editing submission
The planned filing comes amid heightened scrutiny of the FDA’s rare disease stance and a year after Prime deprioritized the program for economic reasons.
-
Alamy
Trump administration
5 FDA decisions to watch in the first quarter of 2026
By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it rejected two years ago.
-
Courtesy of Kyowa Kirin
Kyowa Kirin abandons touted eczema drug following safety review
A month after Amgen gave up on rocatinlimab — which was once seen as a threat to Dupixent — new findings have linked the drug’s mechanism to the onset of a type of skin cancer.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
Sanofi reached a deal for rights to a drug already on the market in China, while UCB is the latest to bet on the ability of T cell engagers to treat autoimmune conditions.
Updated March 4, 2026 -
Alamy
Pierre Fabre seeks to revive US approval chances for spurned cell therapy
Ebvallo is one of a series of rare disease treatments recently turned back by the FDA amid shifting guidance that has surprised some companies and frustrated investors.
-
Permission granted by Candid Therapeutics
Candid, in a reverse merger with RallyBio, to go public
Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly formed company.
-
Getty Images
UniQure says FDA wants another study of Huntington’s gene therapy
Agency staff "strongly recommended" a sham surgery-controlled trial be conducted before an approval filing, a stance one analyst called a "worst case scenario" for UniQure.
-
Getty Images
News roundup
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial
The agency zeroed in on claims that compounded GLP-1 drugs are comparable to approved medicines. Elsewhere, a blood pressure drug topped Wall Street expectations and a Merck deal paid dividends.
-
Bhagavatheeshwaran, Govind. (2016). "MRI Scan" [Image]. Retrieved from Flickr.
Roche pill succeeds in another MS study, but approval questions linger
Liver-related side effects have led some analysts to question fenebrutinib’s prospects, even though the drug has now cleared Phase 3 studies in multiple forms of the disease.
-
Getty Images
Safety concerns spur Aardvark to halt key Prader-Willi drug trial
The detection of certain cardiac issues in a study of healthy volunteers led Aardvark to pause a Phase 3 trial only months before an expected data readout.
-
Sarah Silbiger via Getty Images
Ascendis wins FDA approval of dwarfism drug
Yuviwel, a once-weekly injection, will now compete for market share with BioMarin’s lucrative daily shot Voxzogo.
-
Getty Images
UniQure falls further on Makary comments
Remarks the FDA commissioner made during a CNBC appearance seemed to stoke investor fears that UniQure's gene therapy for Huntington's won't get approved.
-
Getty Images
Startup launchesAtrium spins out of Avidity, aiming to target rare heart diseases with RNA
Four months after Avidity’s $12 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor’s work in cardiovascular disease.
-
Getty Images
IPO windowGenerate caps a strong month for biotech IPOs with $400M offering
The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest new stock offering in nearly three years.
-
Courtesy of Sarepta
Sarepta CEO Doug Ingram to retire, with company at a crossroads
Ingram, who steered the company through multiple drug approvals and controversies, will step aside as Sarepta faces dwindling Elevidys sales and emerging competitors to its core business.
-
Getty Images
Obesity drugsLilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial
Orforglipron, which could be approved for obesity next quarter, proved superior at cutting blood sugar and body weight — but at the expense of higher side effect rates.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Generate Biomedicines’ $400 million offering is the biotech sector’s largest by total proceeds since Acelyrin’s $540 million IPO in May 2023.
Updated Feb. 26, 2026 -
Jacob Bell/BioPharma Dive
VaccinesModerna’s combination flu, COVID shot wins over European drug regulators
In issuing a positive recommendation, the EMA has diverged from the FDA, which has set higher approval standards for Moderna’s vaccine in the U.S.
-
Getty Images
News roundup
Boehringer drug approved in 44 days; BioMarin shelves Roctavian
Boehringer’s lung cancer medicine Hernexeos is the second “national priority” voucher winner to gain a speedy approval. Elsewhere, a landmark gene therapy was withdrawn and a Pfizer deal paid dividends.
